𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

✍ Scribed by Horita, Yosuke; Yamada, Yasuhide; Kato, Ken; Hirashima, Yoshinori; Akiyoshi, Kouhei; Nagashima, Kengo; Nakajima, Takako; Hamaguchi, Tetsuya; Shimada, Yasuhiro

Book ID
118792306
Publisher
Springer
Year
2011
Tongue
English
Weight
334 KB
Volume
17
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

FOLFIRI plus cetuximab versus FOLFIRI pl
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa πŸ“‚ Article πŸ“… 2014 πŸ› Lancet Publishing Group 🌐 English βš– 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow